Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 25.91

+1.5%

Jan 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (646)	8/17/1998 10:39:00 PM
From: Anthony Wong	Read Replies (1) of 1722

Schering-Plough says priority review by FDA Monday August 17, 12:13 pm Eastern Time MADISON, N.J., Aug 17 (Reuters) - Schering-Plough Corp. said Monday that the U.S. Food and Drug Administration has given priority review status to its drug therapy for hepatitis C. Schering-Plough applied for FDA clearance to sell a combination therapy containing Rebetol and Intron on June 17. The therapy is for chronic hepatitis C patients with compensated liver disease. Under priority review status, the FDA will provide action on the drug maker's application to market the new drug within 180 days from the date of filing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next